Tango Therapeutics (TNGX) Equity Ratio (2020 - 2026)

Tango Therapeutics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.9 for Q1 2026.

• In Q1 2026, Equity Ratio rose 47.78% year-over-year to 0.9; the TTM figure through Mar 2026 stood at 0.9 (up 47.78% YoY), while the FY2025 annual figure was 0.87, up 37.74% from the prior year.
• Equity Ratio was 0.9 for Q1 2026 at Tango Therapeutics, up from 0.87 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.9 in Q1 2026 to a low of 0.56 in Q2 2023.
• Historically, Equity Ratio has averaged 0.66 across 5 years, with a median of 0.65 in 2023.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio jumped 103.34% in 2022, then dropped 17.16% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.57 in 2022, then grew by 10.0% to 0.63 in 2023, then gained by 0.27% to 0.63 in 2024, then jumped by 37.74% to 0.87 in 2025, then rose by 3.47% to 0.9 in 2026.
• The last three Equity Ratio figures came in at 0.9 (Q1 2026), 0.87 (Q4 2025), and 0.76 (Q3 2025), per Business Quant data.